Year: 2021

WAKE FOREST, N.C., Dec. 17, 2021 (GLOBE NEWSWIRE) — Wake Forest Bancshares, Inc., (OTC: WAKE) parent company of Wake Forest Federal Savings and Loan Association, announced today that the Company reported earnings of $1,235,550 or $1.13 per share for its fiscal year ended September 30, 2021. The Company’s earnings for the prior fiscal year were $1,170,850 or $1.06 per share. Earnings for the current quarter were reported at $325,400 or $0.30 per share versus $268,550 or $0.24 per share for the quarter ended September 30, 2020. Renee H. Shaw, President and Chief Executive Officer, stated that the Company’s earnings were reflective of improving conditions associated with the re-opening of our economies from COVID 19 pandemic restrictions. The Company’s fiscal year results exceeded expectations and budgetary amounts established at...

Press release Outside trading hours – Regulated information* Brussels, 17 December 2021, 18h Results of the capital increase of KBC Group NV for the employees and effects on the transparency obligations The traditional annual capital increase reserved for the employees of KBC Group NV and some of its Belgian subsidiaries had, dd. 17 December 2021, the following effects on the share capital and the amount of shares/voting rights of KBC Group NV. – The share capital increased by 663 509.34 EUR to 1 459 535 533.42 EUR. – The total number of shares increased by 189 034 to 416 883 592 shares. The total number of voting rights also increased by 189 034 to 416 883 592. The most recent information on the capital and the number of shares of KBC Group NV can be consulted on www.kbc.com.   Transparency legislation aims to create transparency...

Talenom Plc, Stock exchange release 17 December 2021 at 19:00 EET Talenom Plc: Disclosure under chapter 9, section 10 of the securities market act (Allianz SE) Talenom Plc has received an announcement from Allianz SE on 17 December 2021. According to the announcement, the total number of Talenom shares owned by Allianz Vie S.A. increased above 5% of Talenom Plc’s total number of shares as a result of share transactions concluded on 17 December 2021. Total position of Allianz SE according to the notification:  % of shares and voting rights % of shares and voting rights through financial instruments Total of both in % Total number of shares and voting rights of issuerResulting situation on the date on which threshold was crossed or reached 5.02%   5.02% 43,790,252Notified details of the resulting situation on the date on which the...

FORESIGHT SOLAR & TECHNOLOGY VCT PLC LEI: 21380013CXOR8N6OD977 Financial HighlightsOrdinary Shares Total Net Assets as at 30 September 2021: £29.5m Ordinary Shares Net Asset Value per share as at 30 September 2021: 85.4p Foresight Williams Technology Shares Total Net Assets as at 30 September 2021: £12.8m Foresight Williams Technology Shares Net Asset Value per share as at 30 September 2021: 97.0pOrdinary Shares FundNet Asset Value per Ordinary Share at 30 September 2021 was 85.4p, representing an increase of almost 25% from the Net Asset Value per Ordinary Share of 68.9p as at 31 March 2021, following a rebound in market power prices forecast by the energy industry’s independent, external modelling agencies and strong performance in the underlying portfolio. At 30 September 2021, the fund held positions in 11 UK solar assets,...

Protocol Title: The Effect of CBD Gum on Nausea and Vomiting During Pregnancy New York, NY, Dec. 17, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, today announced that it has formally submitted its Clinical Study Protocol (“Protocol”) to the Institutional Review Board (“IRB”).  The Company’s Protocol Title: “The Effect of CBD Gum on Nausea and Vomiting During Pregnancy”. The purpose of this Clinical Study is: to examine the Effects of Different Cannabidiol Doses on Reducing the Frequency and Severity of Nausea in Otherwise Healthy Pregnant Women with Excessive First Trimester Emesis and the Diagnosis of Hyperemesis Gravidarum. Hyperemesis Gravidarum is also known as: Morning Sickness On December 16, 2021 the...

Leuven, 17 December 2021 (17.40 CET) Prof. Dr. Marc De Ceuster becomes new chairman of KBC AncoraPhilippe Vanclooster appointed as independent director On 26 November, Herman Vandaele stepped down as independent director and Chairman of the Board of Directors of Almancora Beheersmaatschappij NV – statutory director of KBC Ancora. The Board of Directors elected Fintrac BV, represented by Prof. Dr. Marc De Ceuster, as the new chairman. To replace Herman Vandaele as director, Philippe Vanclooster was appointed by the General Meeting. New mandates for Prof. Dr. Marc De CeusterIn addition to being chairman of the Board of Directors, Marc De Ceuster also chairs the Nomination Committee and the Remuneration Committee, succeeding Herman Vandaele. In his turn, Marc De Ceuster is succeeded by Philippe Vanclooster as member of the Audit Committee,...

Suominen Corporation ANNOUNCEMENT 17.12.2021          Suominen Corporation: SHARE REPURCHASE 17.12.2021     In the Helsinki Stock Exchange         Trade date 17.12.2021  Bourse trade Buy  Share SUY1V  Amount 9,700 SharesAverage price/ share 5.0332 EURTotal cost 48,822.04 EUR          Suominen Corporation now holds a total of 906 154 sharesincluding the shares repurchased on 17.12.2021          On behalf of Suominen Corporation       Nordea Bank Oyj         Janne Sarvikivi Sami Huttunen       For additional information, please contact:  Toni Tamminen, CFO, Suominen Corporation  tel. +358 (0)10 214 3051         www.suominen.fi    

European Commission decision on marketing authorization anticipated first quarter of 2022 Oxbryta would be the first oral treatment available in Europe to directly inhibit sickle hemoglobin (HbS) polymerization, the underlying molecular cause of sickle cell disease HbS polymerization and red blood cell sickling drive deterioration of red blood cell health and result in hemolysis and hemolytic anemia, leading to inflammation, organ damage and early death SOUTH SAN FRANCISCO, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for Oxbryta® (voxelotor) tablets for the treatment of hemolytic anemia due to sickle...